Aegerion Pharmaceuticals (AEGR) was Reiterated by Leerink Partners to “Outperform” while Lowering the Price Target of the company shares to $ 6 from a previous price target of $15 . Leerink Partners advised their investors in a research report released on May 17, 2016.
On the company’s financial health, Aegerion Pharmaceuticals reported $-1.72 EPS for the quarter, missing the analyst consensus estimate by $ -1.45 based on the information available during the earnings call on May 16, 2016. Analyst had a consensus of $-0.27. The company had revenue of $35.70 million for the quarter, compared to analysts expectations of $43.00 million. The company’s revenue was down -39.9 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.55 EPS.
Aegerion Pharmaceuticals opened for trading at $1.71 and hit $2.36 on the upside on Monday, eventually ending the session at $2.31, with a gain of 33.53% or 0.58 points. The heightened volatility saw the trading volume jump to 13,45,518 shares. Company has a market cap of $68 M.
Aegerion Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company’s products include Juxtapid (lomitapide) and MYALEPT (metreleptin). Lomitapide is a small molecule microsomal triglyceride transfer protein which is marketed under the brand name Juxtapid (lomitapide) capsules (Juxtapid) in the United States as an adjunct to a low-fat diet and other lipid-lowering treatments. Lomitapide was also approved in the European Union under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for homozygous familial hypercholesterolemia (HoFH) in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor and is available as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.